Haleon plc announces changes to the Board

1 May 2024: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces that following Deirdre Mahlan's appointment as President, Chief Executive Officer and Chairperson of the Board of The Duckhorn Portfolio, Inc. (NYSE: NAPA), Deirdre will be stepping down from her role as Non-Executive Director and Chair of the Audit & Risk Committee of Haleon. Deirdre has agreed to continue as Non-Executive Director and Chair of the Audit & Risk Committee of Haleon until a successor has been identified.

Sir Dave Lewis, Haleon's Chair commented: "On behalf of the Board, I would like to thank Deirdre for her considerable contributions to the Board and for chairing the Audit & Risk Committee. I wish her all the best for the future. A search for her successor is now underway."

Contacts

Zoë Bird                +44 7736 746167

Sonya Ghobrial      +44 7392 784784

Email: corporate.media@haleon.com

About Haleon

Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com.